Studies are underway for other GLP-1s to demonstrate effectiveness and safety in this patient population, so there may be more options available in the future
With health insurance, your insurer takes on the risks of protecting you from the unexpected
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment
Potential for Contamination Over time, the preservative components of the medication may break down, increasing the risk of contamination
FDA-approved titration schedules typically involve 4-8 week intervals between dose increases, allowing physiological adaptation to occur
If we take it away, the effect is reduced, so the animals will eat a little bit more now, or GLP-1 is just not as effective as suppressing feeding or suppressing food reward behavior, maybe more specifically, when we take away estrogen, she said